{
  "id": 6409568,
  "title": "Wells Fargo raises Pharvaris stock price target on strong trial data",
  "url": "https://urgent.news/2026/09/09/wells-fargo-raises-pharvaris-stock-price-target-on-strong-trial-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-09T10:40:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/wells-fargo-raises-pharvaris-stock-price-target-on-strong-trial-data-93CH-4893176"
  },
  "original_language": "en",
  "account": "Wells Fargo has increased its price target for Pharvaris B.V. (NASDAQ:PHVS) stock to $65 from $55, maintaining an Overweight rating. The current stock price is $37.84, with analysts setting targets ranging from $40.31 to $79.01. Pharvaris shares have shown a 58% return over the past year, indicating growing investor confidence in the company's clinical pipeline.\n\nThe firm highlighted strong efficacy data for deucrictibant, which demonstrated an 83% reduction in attack rates compared to placebo across all hereditary angioedema (HAE) subtypes, with an even more impressive 87% reduction in Types 1 and 2. Wells Fargo now believes there is a 90% probability of success in the prophylactic indication for deucrictibant XR when using a discounted cash flow-based price target.\n\nDeucrictibant XR's performance in HAE Types 1 and 2 surpasses that of other oral therapies, including TAKHZYRO, ANDEMBRY, and DAWNZERA, which only tested in Type 1 and 2. The drug reduced attack rates by 83% in all HAE types, with statistical significance in every case. In the company's recent Chapter 3 pivotal Phase 3 study, deucrictibant XR showed an 83% reduction in attack rates compared to placebo, and an 87% reduction for HAE Types 1 or 2. The trial met its primary endpoint, and 90% of patients achieved at least a 50% reduction in attacks. Pharvaris has received positive top-line data from this pivotal study, with Oppenheimer and Citizens raising their price targets accordingly. H.C. Wainwright and the European Medicines Agency are also supporting the drug's potential, with a Buy rating and Market Outperform rating, respectively.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Wells Fargo cuts Stryker stock price target on revenue concerns",
        "url": "https://urgent.news/2026/09/09/wells-fargo-cuts-stryker-stock-price-target-on-revenue-concerns",
        "published": "2026-09-09T10:40:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}